Omalizumab in the Prevention of Anaphylaxis During Immunotherapy: A

Postepy Dermatologii I Alergologii - Poland
doi 10.5114/pdia.2014.43192
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Termedia Sp. z.o.o.

Related search

Off-Label Use of Omalizumab in Pediatric Anaphylaxis

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Predictors of Allergic Symptoms and Anaphylaxis During Peanut Oral Immunotherapy

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Anaphylaxis During Specific Subcutaneous Immunotherapy Against Ragweed Allergen -- Case Record

Clinical and Translational Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2014English

The Risk and Management of Anaphylaxis in the Setting of Immunotherapy

American Journal of Rhinology and Allergy
MedicineOtorhinolaryngologyAllergyImmunology
2012English

Alternative Dosing of Omalizumab as an Adjunct Therapy During Multiallergen Oral Immunotherapy in Food Allergic Patients

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Immunotherapy for Mouse Bite Anaphylaxis and Allergy

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2013English

Omalizumab: A Useful Tool for Inducing Tolerance to Bee Venom Immunotherapy

International Journal of Immunopathology and Pharmacology
AllergyImmunologyPharmacology
2016English

Being “SCIT” Careful in the Spring: Analyzing Patterns of Immunotherapy-Induced Anaphylaxis Over the Years

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

PVX108 Peptide Immunotherapy Significantly Reduces Markers of Peanut-Induced Anaphylaxis in a Dose-Dependent Manner

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy